Are meal replacement drinks about weight loss, replacing breakfast, or embracing a new world of personalized smart food?

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

Recently, it has been popularly labeled "nature’s Ozempic," referencing its claimed similarities to the pharmaceutical agent Ozempic (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor ...

“Last time I did go to the doctor, since my A1C was ... pressure reduction, mental health, BMI, and fat tissue decrease. “The most common reason to take a patient off a GLP-1 medication ...

Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP ... reduction versus 5% from baseline for placebo. It also led to a mean body weight reduction of 18 ...

with an average A1C reduction of 1.3% to 1.6% from a baseline of 8%. LLY’s orforglipron is an investigational, once-daily small-molecule oral GLP-1 receptor agonist that can be administered at ...

Orforglipron significantly reduced HbA1c levels by 1.3% (3mg), 1.6% (12mg), and 1.5% (36mg) compared with 0.1% in the placebo arm. Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1) receptor ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP ... A1C, a blood level used to diagnose diabetes, by an average ...

A daily GLP-1 pill can help people with type 2 diabetes regulate ... Those who stayed in the trial for the full 40 weeks and took the lowest dose had a 1.3% reduction in A1C from the participants’ ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped ... Participants saw an average reduction of 1.3% to 1.6% from a baseline of 8%.

A daily pill from drugmaker Eli Lilly has shown similar effectiveness at helping people reduce blood sugar levels and lose weight compared to leading injectable GLP ... A1C, by an average of 1.3 ...